GoodRx/$GDRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GoodRx
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Ticker
$GDRX
Sector
Primary listing
Industry
Health Care Technology
Headquarters
Employees
738
Website
GoodRx Metrics
BasicAdvanced
$1.8B
66.44
$0.07
1.24
-
Price and volume
Market cap
$1.8B
Beta
1.24
52-week high
$9.06
52-week low
$3.68
Average daily volume
1.4M
Financial strength
Current ratio
5.225
Quick ratio
4.46
Long term debt to equity
81.093
Total debt to equity
82.707
Interest coverage (TTM)
1.91%
Profitability
EBITDA (TTM)
111.87
Gross margin (TTM)
93.84%
Net profit margin (TTM)
3.57%
Operating margin (TTM)
11.73%
Effective tax rate (TTM)
40.52%
Revenue per employee (TTM)
$1,080,000
Management effectiveness
Return on assets (TTM)
4.26%
Return on equity (TTM)
4.43%
Valuation
Price to earnings (TTM)
66.442
Price to revenue (TTM)
2.301
Price to book
2.64
Price to tangible book (TTM)
51.3
Price to free cash flow (TTM)
23.191
Free cash flow yield (TTM)
4.31%
Free cash flow per share (TTM)
0.207
Growth
Revenue change (TTM)
4.35%
Earnings per share change (TTM)
-542.97%
3-year revenue growth (CAGR)
0.38%
3-year earnings per share growth (CAGR)
26.64%
What the Analysts think about GoodRx
Analyst ratings (Buy, Hold, Sell) for GoodRx stock.
Bulls say / Bears say
GoodRx's partnership with Boehringer Ingelheim to offer a Humira biosimilar at a 92% discount could significantly enhance its market position and attract more consumers seeking affordable medication options. (reuters.com)
The company's pharma manufacturer solutions revenue saw a substantial 77% increase, indicating strong growth potential in this segment. (businesswire.com)
GoodRx's disciplined capital allocation, including share repurchases and debt reduction, demonstrates a commitment to enhancing shareholder value and financial stability. (businesswire.com)
GoodRx is facing class action lawsuits alleging that it conspired with pharmacy benefit managers to suppress reimbursements to independent pharmacies, which could lead to financial liabilities and reputational damage. (reuters.com)
The company reported a decline in subscription revenue due to the sunset of the Kroger Savings Club partnership, indicating potential challenges in maintaining subscription growth. (businesswire.com)
GoodRx's third-quarter 2024 revenue missed analyst estimates, and the company lowered its full-year revenue guidance, suggesting potential difficulties in meeting growth expectations. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
GoodRx Financial Performance
Revenues and expenses
GoodRx Earnings Performance
Company profitability
GoodRx News
AllArticlesVideos
GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions
Business Wire·4 days ago
GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call
Business Wire·3 weeks ago
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GoodRx stock?
GoodRx (GDRX) has a market cap of $1.8B as of August 01, 2025.
What is the P/E ratio for GoodRx stock?
The price to earnings (P/E) ratio for GoodRx (GDRX) stock is 66.44 as of August 01, 2025.
Does GoodRx stock pay dividends?
No, GoodRx (GDRX) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next GoodRx dividend payment date?
GoodRx (GDRX) stock does not pay dividends to its shareholders.
What is the beta indicator for GoodRx?
GoodRx (GDRX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.